Neuroblastoma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Neuroblastoma}} | {{Neuroblastoma}} | ||
{{CMG}} {{AE}}{{HL}} | {{CMG}} {{AE}}{{ZAS}}{{HL}} | ||
==Overview== | ==Overview== | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
Revision as of 15:42, 21 February 2019
|
Neuroblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neuroblastoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of Neuroblastoma other imaging findings |
|
Risk calculators and risk factors for Neuroblastoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]Haytham Allaham, M.D. [3]
Overview
Other Imaging Findings
Nuclear medicine
- Nuclear medicine studies used for diagnosis of neuroblastoma include fludeoxyglucose-18F positron emission tomography (18F-FDG PET) and metaiodobenzylguanidine (123I-MIBG) scintigraphy.[1]
- 18F-FDG PET scan may distinguish stage 1 and 2 neuroblastoma from other differential diagnosis.
- 123I-MIBG scintigraphy may distinguish stage 3 and 4 neuroblastoma from other differential diagnosis.
- 123I-MIBG scintigraphy is superior than 18F-FDG PET scan in detecting bone marrow metastases.
References
- ↑ Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL (2009). "123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma". J Nucl Med. 50 (8): 1237–43. doi:10.2967/jnumed.108.060467. PMID 19617326.